Argent BioPharma Limited
RGT.L · LSE
6/30/2024 | 12/31/2023 | 6/30/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Market Cap | £0 | £0 | £0 | £0 |
| - Cash | £0 | £0 | £0 | £0 |
| + Debt | £0 | £0 | £0 | £0 |
| Enterprise Value | £0 | £0 | £0 | £0 |
| Revenue | £0 | £0 | £0 | £0 |
| % Growth | -52% | -15.7% | -74.6% | – |
| Gross Profit | -£0 | £0 | £0 | £0 |
| % Margin | -129.1% | 12.1% | 16.2% | 46.3% |
| EBITDA | -£0 | -£0 | -£0 | -£0 |
| % Margin | -3,243.3% | -1,252.6% | -952.6% | -291.5% |
| Net Income | -£0 | -£0 | -£0 | -£0 |
| % Margin | -3,585.8% | -1,180.3% | -1,371.4% | -408.7% |
| EPS Diluted | -0.11 | -0.16 | -1.58 | -2.37 |
| % Growth | 31.3% | 89.9% | 33.3% | – |
| Operating Cash Flow | -£0 | -£0 | -£0 | -£0 |
| Capital Expenditures | -£0 | -£0 | £0 | -£0 |
| Free Cash Flow | -£0 | -£0 | -£0 | -£0 |